Novan Company Profile (NASDAQ:NOVN)

About Novan (NASDAQ:NOVN)

Novan logoNovan, Inc. is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs). The Company's formulation science enables it to further tune the release of nitric oxide when applied to the skin by using the combinations of inactive ingredients. It is developing SB204 for the treatment of acne vulgaris in Phase III. The Company is developing its product candidate, SB206, for the treatment of external genital and perianal warts in Phase II. It is developing SB208, an investigational topical anti-fungal for the treatment of fungal infections of the skin and nails. It is developing SB204 for the treatment of inflammatory skin diseases. Its pipeline also includes SB414, a topical cream product candidate.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Specialty & Advanced Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:NOVN
  • CUSIP: N/A
  • Web: www.novantherapeutics.com
Capitalization:
  • Market Cap: $86.31 million
  • Outstanding Shares: 15,984,000
Average Prices:
  • 50 Day Moving Avg: $6.31
  • 200 Day Moving Avg: $6.31
  • 52 Week Range: $3.52 - $30.90
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.96
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $768,999.00
  • Price / Sales: 112.24
  • Book Value: $0.74 per share
  • Price / Book: 7.30
Profitability:
  • EBIDTA: ($49,040,000.00)
  • Return on Equity: -194.61%
  • Return on Assets: -99.61%
Debt:
  • Current Ratio: 1.97%
  • Quick Ratio: 1.97%
Misc:
  • Average Volume: 117,057 shs.
  • Short Ratio: 1.71
 

Frequently Asked Questions for Novan (NASDAQ:NOVN)

What is Novan's stock symbol?

Novan trades on the NASDAQ under the ticker symbol "NOVN."

How were Novan's earnings last quarter?

Novan Inc (NASDAQ:NOVN) released its quarterly earnings data on Friday, May, 12th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.49) by $0.24. The business earned $0.10 million during the quarter, compared to analysts' expectations of $10.80 million. View Novan's Earnings History.

When will Novan make its next earnings announcement?

Novan is scheduled to release their next quarterly earnings announcement on Monday, November, 13th 2017. View Earnings Estimates for Novan.

Where is Novan's stock going? Where will Novan's stock price be in 2017?

4 equities research analysts have issued 12 month price targets for Novan's shares. Their forecasts range from $8.00 to $31.00. On average, they expect Novan's share price to reach $17.24 in the next twelve months. View Analyst Ratings for Novan.

Who are some of Novan's key competitors?

Who are Novan's key executives?

Novan's management team includes the folowing people:

  • Robert A. Ingram, Independent Chairman of the Board
  • Nathan Stasko Ph.D., President, Chief Scientific Officer, Director
  • G. Kelly Martin, Interim Chief Executive Officer, Director
  • William L. Hodges CPA, Interim Chief Financial Officer, Princiapl Financial Officer, Principal Accounting Officer
  • Stanley Hollenbach J.D., Senior Vice President - Research and Development
  • Jeff N. Hunter, Vice President - Technical Operations
  • Paula Brown Stafford, Chief Development Officer, Director
  • Brian M Johnson, Chief Commercial Officer
  • W. Kent Geer, Independent Director
  • Robert J. Keegan, Independent Director

When did Novan IPO?

(NOVN) raised $46 million in an IPO on Wednesday, September 21st 2016. The company issued 3,800,000 shares at a price of $11.00-$13.00 per share. Piper Jaffray acted as the underwriter for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who owns Novan stock?

Novan's stock is owned by many different of institutional and retail investors. Top institutional investors include Franklin Resources Inc. (1.99%), Vanguard Group Inc. (1.22%), Prospera Financial Services Inc (0.17%) and Goldman Sachs Group Inc. (0.16%). Company insiders that own Novan stock include John W Palmour, Life Sciences Holdings L Malin and Robert Alexander Ingram. View Institutional Ownership Trends for Novan.

Who sold Novan stock? Who is selling Novan stock?

Novan's stock was sold by a variety of institutional investors in the last quarter, including Prospera Financial Services Inc. View Insider Buying and Selling for Novan.

Who bought Novan stock? Who is buying Novan stock?

Novan's stock was acquired by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc. and Vanguard Group Inc.. Company insiders that have bought Novan stock in the last two years include John W Palmour, Life Sciences Holdings L Malin and Robert Alexander Ingram. View Insider Buying and Selling for Novan.

How do I buy Novan stock?

Shares of Novan can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novan's stock price today?

One share of Novan stock can currently be purchased for approximately $5.40.


MarketBeat Community Rating for Novan (NASDAQ NOVN)
Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  60 (Vote Outperform)
Underperform Votes:  65 (Vote Underperform)
Total Votes:  125
MarketBeat's community ratings are surveys of what our community members think about Novan and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Novan (NASDAQ:NOVN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $17.24 (219.31% upside)

Analysts' Ratings History for Novan (NASDAQ:NOVN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/3/2017Piper Jaffray CompaniesReiterated RatingBuyLowView Rating Details
4/12/2017WedbushReiterated RatingNeutral$8.00HighView Rating Details
10/17/2016Credit Suisse GroupInitiated CoverageOutperform$27.00 -> $18.97N/AView Rating Details
10/17/2016JMP SecuritiesInitiated CoverageOutperform$31.00N/AView Rating Details
(Data available from 9/24/2015 forward)

Earnings

Earnings History for Novan (NASDAQ:NOVN)
Earnings by Quarter for Novan (NASDAQ:NOVN)
Earnings History by Quarter for Novan (NASDAQ NOVN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2017        
5/12/2017Q1 2017($0.49)($0.73)$10.80 million$0.10 millionViewN/AView Earnings Details
3/20/2017Q4 16($1.14)($0.82)ViewN/AView Earnings Details
11/14/2016Q3 16($1.40)($5.76)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Novan (NASDAQ:NOVN)
2017 EPS Consensus Estimate: ($1.47)
2018 EPS Consensus Estimate: ($1.26)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.19)($0.19)($0.19)
Q2 20171($0.67)($0.67)($0.67)
Q3 20171($0.32)($0.32)($0.32)
Q4 20171($0.29)($0.29)($0.29)
Q1 20181($0.21)($0.21)($0.21)
Q2 20181($0.27)($0.27)($0.27)
Q3 20181($0.35)($0.35)($0.35)
Q4 20181($0.43)($0.43)($0.43)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Novan (NASDAQ:NOVN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Novan (NASDAQ:NOVN)
Insider Ownership Percentage: 10.72%
Institutional Ownership Percentage: 6.05%
Insider Trades by Quarter for Novan (NASDAQ:NOVN)
Institutional Ownership by Quarter for Novan (NASDAQ:NOVN)
Insider Trades by Quarter for Novan (NASDAQ:NOVN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/29/2017Robert Alexander IngramDirectorBuy12,000$4.57$54,840.00View SEC Filing  
8/23/2017John W PalmourDirectorBuy12,000$3.99$47,880.00View SEC Filing  
9/26/2016Life Sciences Holdings L MalinMajor ShareholderBuy800,000$11.00$8,800,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Novan (NASDAQ:NOVN)
Latest Headlines for Novan (NASDAQ:NOVN)
Source:
DateHeadline
americanbankingnews.com logoNovan Inc (NOVN) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - September 22 at 10:10 AM
finance.yahoo.com logoNovartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries
finance.yahoo.com - September 22 at 9:17 AM
americanbankingnews.com logoSupernus Pharmaceuticals (SUPN) versus NOVAN INC (NOVN) Head to Head Analysis
www.americanbankingnews.com - September 21 at 12:32 PM
americanbankingnews.com logoNovan Inc (NOVN) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - September 21 at 2:34 AM
finance.yahoo.com logoNovartis' Xolair® confirms re-treatment efficacy in chronic spontaneous urticaria patients after treatment interruption
finance.yahoo.com - September 17 at 5:40 AM
americanbankingnews.com logoNovan Inc (NOVN) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - September 16 at 7:08 PM
americanbankingnews.com logoComparing NOVAN INC (NOVN) & Its Competitors
www.americanbankingnews.com - September 13 at 6:20 AM
americanbankingnews.com logoAbbVie (ABBV) vs. Novan (NOVN) Critical Review
www.americanbankingnews.com - September 8 at 4:14 PM
finance.yahoo.com logoNovartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018.
finance.yahoo.com - September 4 at 1:12 AM
americanbankingnews.com logoRobert Alexander Ingram Buys 12,000 Shares of Novan Inc (NOVN) Stock
www.americanbankingnews.com - August 29 at 7:56 PM
americanbankingnews.com logoNovan Inc (NOVN) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - August 27 at 2:50 AM
americanbankingnews.com logoJohn W. Palmour Acquires 12,000 Shares of Novan Inc (NOVN) Stock
www.americanbankingnews.com - August 25 at 8:34 PM
streetinsider.com logoNovan (NOVN) Appoints Paula Stafford to Board of Directors
www.streetinsider.com - August 17 at 6:15 AM
americanbankingnews.com logoQ2 2017 EPS Estimates for Novan Inc (NASDAQ:NOVN) Cut by Wedbush
www.americanbankingnews.com - August 7 at 7:04 AM
americanbankingnews.com logoNovan Inc (NASDAQ:NOVN) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - August 3 at 12:52 AM
americanbankingnews.com logoValuEngine Downgrades Novan Inc (NASDAQ:NOVN) to Strong Sell
www.americanbankingnews.com - August 2 at 10:20 PM
americanbankingnews.com logoAnalyzing Assembly Biosciences (ASMB) & Novan (NOVN)
www.americanbankingnews.com - August 2 at 12:16 AM
americanbankingnews.com logoHead to Head Comparison: Rockwell Medical (RMTI) versus Novan (NASDAQ:NOVN)
www.americanbankingnews.com - August 1 at 10:26 PM
americanbankingnews.com logoHead-To-Head Review: DARA Biosciences (DARA) & Novan (NOVN)
www.americanbankingnews.com - August 1 at 8:30 PM
americanbankingnews.com logoZacks: Novan Inc (NASDAQ:NOVN) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - July 31 at 2:26 PM
americanbankingnews.com logoEagle Pharmaceuticals (EGRX) versus NOVAN INC (NASDAQ:NOVN) Head-To-Head Comparison
www.americanbankingnews.com - July 29 at 6:08 PM
americanbankingnews.com logoNovan Inc (NASDAQ:NOVN) Short Interest Down 26.4% in July
www.americanbankingnews.com - July 29 at 7:14 AM
americanbankingnews.com logo Novan Inc (NASDAQ:NOVN) Given $9.50 Average Target Price by Brokerages
www.americanbankingnews.com - July 28 at 8:24 PM
feeds.benzinga.com logo18 Biggest Mid-Day Gainers For Friday
feeds.benzinga.com - July 28 at 1:17 PM
americanbankingnews.com logo Novan Inc. (NASDAQ:NOVN) Given $9.50 Consensus Target Price by Brokerages
www.americanbankingnews.com - July 24 at 9:56 AM
americanbankingnews.com logoCritical Contrast: Aimmune Therapeutics (AIMT) versus Novan (NOVN)
www.americanbankingnews.com - July 22 at 6:29 PM
americanbankingnews.com logoTherapeuticsMD (TXMD) and Novan (NASDAQ:NOVN) Financial Review
www.americanbankingnews.com - July 13 at 8:10 AM
americanbankingnews.com logo Novan Inc. (NOVN) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - June 22 at 8:14 AM
americanbankingnews.com logoNovan Inc (NOVN) Sees Significant Decrease in Short Interest
www.americanbankingnews.com - May 31 at 7:12 AM
americanbankingnews.com logoZacks: Novan Inc (NOVN) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 30 at 10:47 PM
americanbankingnews.com logoZacks Investment Research Lowers Novan Inc (NOVN) to Hold
www.americanbankingnews.com - May 28 at 8:36 AM
americanbankingnews.com logoNovan Inc Expected to Post Q2 2017 Earnings of ($0.57) Per Share (NOVN)
www.americanbankingnews.com - May 17 at 7:46 AM
americanbankingnews.com logoZacks: Brokerages Anticipate Novan Inc (NOVN) to Announce -$0.58 Earnings Per Share
www.americanbankingnews.com - May 16 at 2:18 PM
americanbankingnews.com logoNovan Inc (NOVN) Posts Earnings Results, Misses Estimates By $0.24 EPS
www.americanbankingnews.com - May 15 at 11:18 AM
americanbankingnews.com logoNovan Inc (NOVN) Sees Significant Increase in Short Interest
www.americanbankingnews.com - May 13 at 7:20 AM
americanbankingnews.com logoZacks: Analysts Set $9.50 Target Price for Novan Inc (NOVN)
www.americanbankingnews.com - May 6 at 12:34 AM
finance.yahoo.com logoNovartis exercises exclusive option agreement with Conatus for the treatment of NASH
finance.yahoo.com - May 4 at 11:19 AM
finance.yahoo.com logoNovan Presents Preclinical Data from Inflammatory Skin Diseases Program
finance.yahoo.com - April 27 at 10:05 AM
finance.yahoo.com logoNovan Presents Safety Data for SB204 Program
finance.yahoo.com - April 27 at 10:05 AM
finance.yahoo.com logoAlcon announces EU launch of CyPass® Micro-Stent, a micro invasive glaucoma surgical device, to lower intraocular pressure (IOP) in patients with primary open-angle glaucoma
finance.yahoo.com - April 26 at 6:24 PM
americanbankingnews.com logo Novan Inc (NOVN) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - April 20 at 8:28 PM
finance.yahoo.com logoNovartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL
finance.yahoo.com - April 18 at 10:06 AM
americanbankingnews.com logoNovan Inc (NOVN) Given a $11.00 Price Target by Piper Jaffray Companies Analysts
www.americanbankingnews.com - April 18 at 7:47 AM
streetinsider.com logoPre-Open Stock Movers 04/12: (NOVN) (NBIX) (BBRY) Higher; (NS) (ONVO) (TSCO) Lower (more...)
www.streetinsider.com - April 13 at 8:14 AM
americanbankingnews.com logoNovan Inc (NOVN) Receives "Neutral" Rating from Wedbush
www.americanbankingnews.com - April 12 at 2:01 PM
feeds.benzinga.com logo11 Biggest Mid-Day Gainers For Wednesday
feeds.benzinga.com - April 12 at 1:36 PM
msn.com logo19 Stocks Moving In Wednesday's Pre-Market Session
www.msn.com - April 12 at 10:25 AM
rttnews.com logoNovan Inc. (NOVN) Is Up Sharply On Phase 2 Study Results
www.rttnews.com - April 12 at 10:25 AM
finance.yahoo.com logoNovan Reports Positive Topline Results with SB208 in Phase 2 Trial
finance.yahoo.com - April 12 at 10:25 AM
finance.yahoo.com logoNovan's stock rockets after positive trial results
finance.yahoo.com - April 12 at 10:25 AM

Social

Chart

Novan (NOVN) Chart for Sunday, September, 24, 2017

This page was last updated on 9/24/2017 by MarketBeat.com Staff